Bengaluru (Karnataka) [India], Sep 24 (ANI): Biopharmaceuticals major Biocon Ltd said on Tuesday that its subsidiary has acquired research and development capital assets from Pfizer Healthcare India Ltd.
“The high-end integrated R&D facility in Chennai will enable Biocon Biologics to expand its capability and accelerate the journey towards meeting its strategic long-term goal of addressing the needs of millions of patients worldwide,” said Chief Executive Officer CĀ hristiane Hamacher.
The 60,000 square feet facility in Chennai will house an early-stage research and innovation centre including a pilot-scale R&D unit equipped with cell line development, drug substance process development from bench scale to 400-litre scale bioreactors, drug product formulation laboratories and analytical R&D laboratories.
The facility is expected to be operational in a few months post qualification and will house over 250 scientists who will have access to R&D labs equipped with over 500 high-end process and analytical instrumentation.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
“This investment will allow us to fast-forward the development of our biosimilars from lab to pilot scale. R&D is at the core of what we do. I believe this facility will enable us to pursue breakthrough innovation in pursuit of providing affordable access to high-quality biosimilars and inclusive healthcare solutions aimed at transforming patient lives globally,” said Hamacher in a statement.
Currently, Biocon Biologics has a two lakh square feet R&D Centre at Biocon Park in Bengaluru . The company has a product pipeline of 28 molecules, including 11 with Mylan, few with Sandoz and rest on its own. (ANI)
Date: September 30, 2019
Source: ANI News